LUNG
Pulmonx Corporation
LUNG lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
LUNG Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Unavailable |
LUNG's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LUNG PE Valuation
LUNG has no meaningful PE right now: it lost money over the past year.
LUNG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect LUNG's losses to shrink, with revenue growing.
LUNG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.01 | +$0.40 |
| Q2 2026 | -$1.16 | +$0.27 |
| Q1 2026 | -$1.30 | +$0.14 |
| Q4 2025 | -$1.33 | +$0.11 |
| Q3 2025 | -$1.41 | +$0.06 |
| Q2 2025 | -$1.43 | +$0.07 |
| Q1 2025 | -$1.44 | +$0.10 |
| Q4 2024 | -$1.44 | +$0.16 |
LUNG is still losing money, but far less than before: $1.01 per share over the past year, against $2.32 at its worst in mid-2021.
LUNG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $22.8M | +6.2% |
| Q2 2026 | $22.8M | -4.6% |
| Q1 2026 | $20.6M | -8.7% |
| Q4 2025 | $22.6M | -4.9% |
| Q3 2025 | $21.5M | +5.5% |
| Q2 2025 | $23.9M | +15% |
| Q1 2025 | $22.5M | +20% |
| Q4 2024 | $23.8M | +23% |
LUNG's revenue grew through 2024 and has held roughly level since: $23M last quarter, up 6.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -33% | +34 points |
| Q2 2026 | -40% | +22 points |
| Q1 2026 | -63% | +1.7 points |
| Q4 2025 | -44% | +13 points |
| Q3 2025 | -67% | +2.4 points |
| Q2 2025 | -62% | +13 points |
| Q1 2025 | -65% | +13 points |
| Q4 2024 | -56% | +16 points |
LUNG's operating margin was −33% last quarter, up 34 points from the same quarter a year ago, near the top of its range since 2019.
LUNG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.2M | +$5.1M |
| Q2 2026 | -$5.2M | -$1.3M |
| Q1 2026 | -$10.1M | +$3.4M |
| Q4 2025 | -$7.1M | -$256K |
| Q3 2025 | -$8.3M | -$593K |
| Q2 2025 | -$4M | +$2.3M |
| Q1 2025 | -$13.5M | -$1.3M |
| Q4 2024 | -$6.8M | +$1.8M |
LUNG has burned cash in almost every quarter: −$26M over the past year, against −$33M the year before.
LUNG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.7% | +708K shares |
| 1 year | +5.5% | +2.2M shares |
| 3 years | +13% | +5.1M shares |
| 5 years | +18% | +6.7M shares |
LUNG has 43M diluted shares, up 5.5% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | $27,000 |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | $26,000 |
LUNG Net Leverage
LUNG's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LUNG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.3 | Neutral |
| Stochastic | 76.2 | Neutral |
LUNG's weekly RSI is 64 (neutral) and its Stochastic is 76 (neutral).
LUNG PE vs Healthcare Sector
LUNG has no meaningful PE right now: it lost money over the past year.
LUNG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.22 | 35% above |
| 20 week MA | $2.01 | 49% above |
| 50 week MA | $1.79 | 68% above |
| 100 week MA | $2.87 | 4.5% above |
| 200 week MA | $6.30 | 52% below |
LUNG has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 52% below its 200-week average.
LUNG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $41.9 | $65.2 | +56% |
| 2021 | $65.2 | $33.0 | -49% |
| 2022 | $33.0 | $7.85 | -76% |
| 2023 | $7.85 | $12.8 | +62% |
| 2024 | $12.8 | $6.70 | -47% |
| 2025 | $6.70 | $2.22 | -67% |
| 2026 YTD | $2.22 | $3.00 | +35% |
LUNG is up 35% so far in 2026, after finishing lower in four of the previous six years.